Technical Analysis for GH - Guardant Health, Inc.

Grade Last Price % Change Price Change
grade B 159.29 1.28% 2.02
GH closed up 1.28 percent on Friday, January 15, 2021, on 86 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical GH trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Slingshot Bullish Bullish Swing Setup 1.28%
Calm After Storm Range Contraction 1.28%
Upper Bollinger Band Walk Strength 1.28%
Multiple of Ten Bearish Other 1.28%
Older End-of-Day Signals for GH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Guardant Health, Inc. Description

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.


Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Disease Oncology Telemedicine Telehealth Lab Testing Precision Medicine Blood Test Blood Tests Reimbursement Biopsy Healthcare Costs

Is GH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 163.42
52 Week Low 55.9
Average Volume 1,071,435
200-Day Moving Average 98.44
50-Day Moving Average 125.38
20-Day Moving Average 137.52
10-Day Moving Average 145.70
Average True Range 6.35
ADX 28.87
+DI 37.02
-DI 13.54
Chandelier Exit (Long, 3 ATRs ) 144.37
Chandelier Exit (Short, 3 ATRs ) 139.12
Upper Bollinger Band 162.99
Lower Bollinger Band 112.04
Percent B (%b) 0.93
BandWidth 37.05
MACD Line 9.48
MACD Signal Line 6.78
MACD Histogram 2.7081
Fundamentals Value
Market Cap 15.92 Billion
Num Shares 100 Million
EPS -1.28
Price-to-Earnings (P/E) Ratio -124.35
Price-to-Sales 41.99
Price-to-Book 10.86
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 168.20
Resistance 3 (R3) 167.78 164.40 166.72
Resistance 2 (R2) 164.40 162.13 164.61 166.22
Resistance 1 (R1) 161.84 160.73 163.12 162.26 165.72
Pivot Point 158.46 158.46 159.10 158.67 158.46
Support 1 (S1) 155.90 156.19 157.18 156.32 152.86
Support 2 (S2) 152.52 154.79 152.73 152.36
Support 3 (S3) 149.96 152.52 151.87
Support 4 (S4) 150.38